Johnson & Johnson

JNJPre-clinical

Founded in 1886, Johnson & Johnson operates as a multinational healthcare corporation headquartered in New Brunswick, New Jersey. The company's pharmaceutical division, Janssen, is a global leader in oncology, immunology, and neuroscience with blockbuster drugs like Stelara, Darzalex, and Remicade. J&J combines deep scientific expertise with extensive global reach, serving patients in over 175 countries while maintaining one of the industry's strongest R&D pipelines.

Market Cap

$11.9B

Employees

140,000-150,000

Focus

Biotech

JNJ · Stock Price

USD 10.75+3.27 (+43.63%)

Historical price data

AI Company Overview

Technology Platform

Diversified healthcare platform combining pharmaceutical R&D, medical device innovation, and consumer health products, with focus on monoclonal antibodies, CAR-T cell therapy, and digital health technologies.

Pipeline Snapshot

721

721 drugs in pipeline, 244 in Phase 3

Drug	Indication	Stage
Placebo + Cisapride	Infant, Premature	Approved
OROS-methylphenidate	Attention Deficit Hyperactivity Disorder	Approved
Sodium hypochlorite (bleach) baths + Mupirocin ointment + Water + Petrolatum Ointment	Atopic Dermatitis	Approved
Risperidone	Schizophrenia	Approved
paliperidone	Schizophrenia	Approved

FDA Approved Drugs

OXYGEN, USPNDAJul 5, 2013

CIDA-STATNDAJul 22, 1986

CHG SCRUBNDAJul 22, 1986

Opportunities

J&J is positioned for growth through its robust late-stage pipeline, expansion in CAR-T therapy and precision medicine, and continued investment in digital health technologies.

The company's diversified portfolio provides stability while enabling strategic focus on high-growth therapeutic areas.

Risk Factors

Key risks include patent cliffs for major products like Stelara, increasing biosimilar competition, ongoing litigation challenges, and regulatory pressures on drug pricing.

The company must also successfully integrate acquisitions while maintaining innovation momentum.

Competitive Landscape

J&J competes with pharmaceutical giants like Roche, Pfizer, AbbVie, and Merck, differentiating through its diversified healthcare portfolio, strong presence in oncology and immunology, and extensive global reach. The company's financial strength and R&D capabilities provide competitive advantages in strategic acquisitions and pipeline development.

Publications

Patents

Pipeline

721

FDA Approvals